Japan Generics Policy To Spark Mergers Among Makers
This article was originally published in PharmAsia News
Executive Summary
Japan's inauguration of a generics promotion campaign in April is expected to lead to an increase in consolidations by makers of the drugs. The Japan generics market, counted at $3.41 billion in 2006, is expected to grow sharply after the new policy gets under way. The policy spurs a need for generics makers to become bigger so they can serve a larger market. Nichiiko Pharmaceutical-Teikoko Medix KK, Zydus Cadilla Group-Nippon Universal Pharmaceutical and India's Lupin and Kyowa Pharmaceutical are examples of recent mergers. (Click here for more - a subscription may be required)
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.